NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
about
Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment OptionsPharmGKB summary: very important pharmacogene information for N-acetyltransferase 2Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysisCytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohortThe incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control studyA retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergyPharmacogenetics of isoniazid-induced hepatotoxicity.NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid.Latest advances in predicting DILI in human subjects: focus on biomarkers.Drug-induced liver injury: the role of drug metabolism and transport.Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies.Drug metabolism and liver disease: a drug-gene-environment interaction.Improved genotyping of N-acetyltransferase 2: role of the ultra-slow acetylators.PharmGKB summary: isoniazid pathway, pharmacokinetics.Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians.Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group
P2860
Q26781892-E3074CBF-DD00-4059-B743-205DDC2390DEQ27011622-1FD0F682-5F7D-46D7-9975-C342A2898DC2Q28484468-653CB46C-7074-4210-9723-C54294D9754FQ28486869-8C70BA5D-4F47-44BB-947F-5C372124F64CQ28539060-0171653D-C325-4AF6-B489-8D0B302CCF5FQ28544822-11F0119C-207B-43FC-91B3-BC86C697E47BQ33974514-A8843C09-D08F-4FFE-BF45-15CC7199BB03Q35669887-0B4595CF-66D0-4301-ADA1-0691DDB16A0DQ35934555-737C25F6-3BB6-4FB6-BD21-4D4772A27511Q36867088-8F47A14C-B747-40C3-A823-C5A41A7411FDQ38045377-ED9841DE-3EE8-492A-8B17-EE9D75FDB056Q38084215-0F3A59A1-F8E5-490E-8226-5634D0E7C1A0Q38381479-A025BA46-6614-40DD-A431-5589C28120F3Q39037269-596865ED-619F-46FD-9315-493F7B7A118FQ39336687-FC60A8E1-2ADC-43FB-AE95-A6F4662DF744Q42090708-2F751AD9-767B-445C-9A6B-3C9CED21E464Q42696912-A1BD6687-870F-4AE6-9BD9-ADE2AECFF226Q42708451-4D8B5994-54F8-4424-A8B5-9F22D543D89EQ43474583-33CD7818-E3EB-4374-A17C-68AFB6CEB6ADQ43885443-6ABF15A4-A85B-49F5-BABD-E00CD58628A5Q45344839-E6C125E9-4957-4A7A-A0FA-B755028A5994Q45766101-92349ED6-21B0-420B-8515-BA53CF464368Q51569750-E27A2E71-5BD0-4692-A58C-0F778610CDCFQ53765768-F85F80D4-B9C5-4D0C-8036-C21D1BCDFD14Q57302643-8FE6388A-C6FF-49C8-89BB-203528BB62FB
P2860
NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
NAT2 and CYP2E1 polymorphisms ...... otoxicity in Chinese patients.
@en
NAT2 and CYP2E1 polymorphisms ...... otoxicity in Chinese patients.
@nl
type
label
NAT2 and CYP2E1 polymorphisms ...... otoxicity in Chinese patients.
@en
NAT2 and CYP2E1 polymorphisms ...... otoxicity in Chinese patients.
@nl
prefLabel
NAT2 and CYP2E1 polymorphisms ...... otoxicity in Chinese patients.
@en
NAT2 and CYP2E1 polymorphisms ...... otoxicity in Chinese patients.
@nl
P2093
P2860
P1476
NAT2 and CYP2E1 polymorphisms ...... otoxicity in Chinese patients.
@en
P2093
Jun-Xian Zhang
Xue-Qiong Wu
Zhong-Yuan Wang
P2860
P304
P356
10.1111/J.1440-1681.2012.05713.X
P577
2012-06-01T00:00:00Z